Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | VP, CONTROLLER | February 28, 2023 | March 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date February 28, 2023 · Filed March 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 33,149 |
Reported balance
After 2023-02-28 transaction · row 1
1 source rowRow 1 · 2023-02-28 · Tax withholding · Disposed 11,182 · Balance 33,149 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2023 Filed Mar 2, 2023 22:03 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 11,182 | $154.28 | $1,725,158.96 |
DisclosureSEC source: 0001415889-23-003853 · form4-03022023_100331.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, CONTROLLER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,149 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:08 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 6,752 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002941 · form4-02212023_110237.xml · derivative · entry 5 Durkin Brian L · CIK 0001756865 · VP, CONTROLLER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,752 Underlying: Common Stock · 6,752 shares Expires 2033-02-15 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,251 on February 16, 2024, 2,251 on February 16, 2025, and 2,251 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:08 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002941 · form4-02212023_110237.xml · nonDerivative · entry 4 Durkin Brian L · CIK 0001756865 · VP, CONTROLLER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,331 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:08 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 3,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002941 · form4-02212023_110237.xml · nonDerivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, CONTROLLER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,025 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:08 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 3,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002941 · form4-02212023_110237.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, CONTROLLER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,879 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:08 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 16,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002941 · form4-02212023_110237.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, CONTROLLER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,136 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 11,682 | $79.02 Strike: $79.02 | $923,111.64 |
DisclosureSEC source: 0001179110-22-002147 · edgar.xml · derivative · entry 4 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,682 shares Expires 2029-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 6,946 | $150.00 | $1,041,905.56 |
DisclosureSEC source: 0001179110-22-002147 · edgar.xml · nonDerivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,094 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:05 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 11,682 | $150.01 | $1,752,395.79 |
DisclosureSEC source: 0001179110-22-002147 · edgar.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,040 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.04 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 11,682 | $79.02 | $923,111.64 |
DisclosureSEC source: 0001179110-22-002147 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:11 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 7,589 | $149.54 | $1,134,859.06 |
DisclosureSEC source: 0001179110-22-001839 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,040 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:34 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to Buy) · Derivative | 10,945 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001510 · edgar.xml · derivative · entry 5 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,945 Underlying: Common Stock · 10,945 shares Expires 2032-02-16 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,649 on February 17, 2023, 3,648 on February 17, 2024, and 3,648 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:34 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001510 · edgar.xml · nonDerivative · entry 4 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,629 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:34 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 3,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001510 · edgar.xml · nonDerivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,875 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:34 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001510 · edgar.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,132 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:34 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 8,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001510 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,235 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 22:29 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 7,180 | $61.36 Strike: $0.00 | $440,564.80 |
DisclosureSEC source: 0001179110-21-011176 · edgar.xml · derivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,180 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 22:29 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 11,790 | $128.51 | $1,515,132.90 |
DisclosureSEC source: 0001179110-21-011176 · edgar.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,505 Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 22:29 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 7,180 | $61.36 | $440,564.80 |
DisclosureSEC source: 0001179110-21-011176 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:29 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 2,392 | $107.74 | $257,714.08 |
DisclosureSEC source: 0001179110-21-002601 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,115 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 15,527 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002042 · edgar.xml · derivative · entry 5 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,527 Underlying: Common stock · 15,527 shares Expires 2031-02-17 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,176 on February 18, 2022, 5,176 on February 18, 2023, and 5,175 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 3,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002042 · edgar.xml · nonDerivative · entry 4 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,507 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002042 · edgar.xml · nonDerivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,764 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 574 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002042 · edgar.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,867 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002042 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,293 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. F5 · balance_after: The total shown in this column reflects an update to correct a previous administrative error in the amount of securities beneficially owned by the reporting person. Read SEC document |
| May 08, 2020 Filed May 12, 2020 21:44 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 60 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-005829 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,704 F1 · price: Received in exchange for 70 shares of Allergan plc common stock in connection with its acquisition by AbbVie Inc. Allergan shareholders received 0.8660 AbbVie shares for each Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020). Read SEC document |
| March 30, 2020 Filed Mar 20, 2020 20:56 UTC | AbbVie Inc. ABBV · Entity 2800 | PurchaseCommon Stock, $0.01 par value | 750 | $69.00 | $51,750.00 |
DisclosureSEC source: 0001179110-20-004028 · edgar.xml · nonDerivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,844 Read SEC document |
| March 20, 2020 Filed Mar 20, 2020 21:34 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | PurchaseCommon Stock, $0.01 par value | 750 | $69.00 | $51,750.00 |
DisclosureSEC source: 0001179110-20-004036 · edgar.xml · nonDerivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,844 F2 · date: This amendment is filed to correct the date of this transaction. Read SEC document |
| March 20, 2020 Filed Mar 20, 2020 21:34 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | PurchaseCommon Stock, $0.01 par value | 800 | $67.50 | $54,000.00 |
DisclosureSEC source: 0001179110-20-004036 · edgar.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,094 Read SEC document |
| March 20, 2020 Filed Mar 20, 2020 20:56 UTC | AbbVie Inc. ABBV · Entity 2800 | PurchaseCommon Stock, $0.01 par value | 800 | $67.50 | $54,000.00 |
DisclosureSEC source: 0001179110-20-004028 · edgar.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,094 Read SEC document |
| March 20, 2020 Filed Apr 24, 2020 21:07 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | PurchaseCommon Stock, $0.01 par value | 1,550 | $69.00 | $106,950.00 |
DisclosureSEC source: 0001179110-20-005097 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,644 F1 · shares: This amendment is being filed to correctly indicate the number of shares purchased by the reporting person on March 20, 2020. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 21:34 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | PurchaseCommon Stock, $0.01 par value | 2,200 | $68.18 | $150,004.80 |
DisclosureSEC source: 0001179110-20-004036 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,294 Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 20:56 UTC | AbbVie Inc. ABBV · Entity 2800 | PurchaseCommon Stock, $0.01 par value | 2,200 | $68.18 | $150,004.80 |
DisclosureSEC source: 0001179110-20-004028 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,294 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 1,941 | $85.42 | $165,800.22 |
DisclosureSEC source: 0001179110-20-002853 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,094 Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 24,549 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001179110-20-002139 · edgar.xml · derivative · entry 6 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,549 Underlying: Common Stock · 24,549 shares Expires 2030-02-19 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,183 on February 20, 2021, 8,183 on February 20, 2022, and 8,183 on February 20, 2023. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002139 · edgar.xml · nonDerivative · entry 4 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,035 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. F7 · balance_after: The total number of securities beneficially owned by the reporting person is updated to correct an administrative error in a previous Form 4. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 574 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002139 · edgar.xml · nonDerivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,136 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002139 · edgar.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,562 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002139 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,487 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 21:03 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 613 | $67.46 | $41,352.98 |
DisclosureSEC source: 0001179110-19-008843 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,508 Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 20:34 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 475 | $79.69 | $37,852.75 |
DisclosureSEC source: 0001179110-19-004224 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,121 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:54 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 758 | $79.41 | $60,192.78 |
DisclosureSEC source: 0001179110-19-003077 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,596 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 11,682 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002360 · edgar.xml · derivative · entry 6 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,682 Underlying: Common Stock · 11,682 shares Expires 2029-02-20 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,894 on February 21, 2020, 3,894 on February 21, 2021, and 3,894 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 576 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002360 · edgar.xml · nonDerivative · entry 4 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,354 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 1,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002360 · edgar.xml · nonDerivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,869 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 874 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002360 · edgar.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,159 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:16 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 1,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002360 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,464 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.